Article
Loss of HMCES is synthetic lethal with APOBEC activity in cancer cells
2021-02-06
Abstract excerpt
Analysis of cancer mutagenic signatures provides information about the origin of mutations and can inform the use of clinical therapies, including immunotherapy. In particular, APOBEC3A (A3A) has emerged as a major driver of mutagenesis in cancer cells and its expression results in DNA damage and susceptibility to treatment with inhibitors of the ATR and CHK1 checkpoint kinases. Here we report the implementation o...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 4285e23c-48a2-52b3-bd4f-be8af834e372
- DOI
- 10.1101/2021.02.05.429803
